ReviewReviews in endocrine & metabolic disorders2021
Lean NAFLD: an underrecognized and challenging disorder in medicine.
Review in Reviews in endocrine & metabolic disorders, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
53 citing papers in PubMed, 2 syntheses or guidelines pooled it, 74 citations in OpenAlex.
- Long-term outcomes in lean and non-lean NAFLD patients: a systematic review and meta-analysis.Endocrine · 2024Pooled it
- Epidemiology of lean/non-obese nonalcoholic fatty liver disease in China: A systematic review and meta-analysis.Saudi medical journal · 2023Pooled it
- Culturally adapted hypocaloric diet improves hepatic steatosis, inflammatory and oxidative biomarkers in Egyptian MASLD patients: a single-arm interventional study.Lipids in health and disease · 2025Trial
- Estimated Body Fat Percentage and Triglyceride-Glucose Index for Identifying MASLD in Lean Asian Adults: A Cross-Sectional Analysis.The Kaohsiung journal of medical sciences · 2026Article
- [Key determinants of global burden of non-alcoholic fatty liver disease: machine learning combined with Mendelian randomization analysis based on GBD data].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2026Article
- Interpreting the triglyceride-glucose index and its derived indices in metabolic dysfunction-associated steatotic liver disease: clinical utility and evidence gaps.Frontiers in medicine · 2026Review
- Fructose and follistatin potentiate acute MASLD during complete hepatic insulin resistance.Nature communications · 2025Article
- Cross-ancestry discovery of genetic risk variants for lean metabolic dysfunction-associated steatotic liver disease.Cell & bioscience · 2025Article
- [Research progress on clinical characteristics and pathological mechanisms of lean metabolic-associated fatty liver disease].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2025Review
- Differential risk factors of fibrosis between lean and obese MAFLD.Clinical and experimental medicine · 2025Article
- Effect of lean status on the mortality of patients with non-alcoholic fatty liver disease (NAFLD): A systematic review and meta-analysis.Pakistan journal of medical sciences · 2025Review
- The relationship between serum uric acid level and non-alcoholic fatty liver disease in northern China: a retrospective cohort study.BMC public health · 2025Article
- Current Therapeutic Landscape for Metabolic Dysfunction-Associated Steatohepatitis.International journal of molecular sciences · 2025Review
- Sex differences in murine MASH induced by a fructose-palmitate-cholesterol-enriched diet.JHEP reports : innovation in hepatology · 2025Article
- The global landscape of lean metabolic dysfunction-associated steatotic liver disease: insight from Asia and the West.Frontiers in gastroenterology (Lausanne, Switzerland) · 2025Review
- Risk Factors for Non-alcoholic Fatty Liver Disease from the Perspective of Medical Professionals: A Systematic Review and Expert Opinion.Middle East journal of digestive diseases · 2025Review
- Thiostrepton: multifaceted biological activities and its applications in treatment of inflammatory diseases.Inflammopharmacology · 2025Review
- Review
- Metabolic dysfunction associated fatty liver disease in healthy weight individuals.Hepatology international · 2024Review
- Inflammatory Bowel Disease Is an Independent Risk Factor for Metabolic Dysfunction-Associated Steatotic Liver Disease in Lean Individuals.Inflammatory bowel diseases · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
Abstract
Classically, Non-Alcoholic Fatty Liver Disease (NAFLD) has been thought to be driven by excessive weight gain and obesity. The overall greater awareness of this disorder has led to its recognition in patients with normal body mass index (BMI). Ongoing research has helped to better understand potential causes of Lean NAFLD, the risks for more advanced disease, and potential therapies. Here we review the recent literature on prevalence, risk factors, severity of disease, and potential therapeutic interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.